Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 30 of 35.
Aug 2011
22 Aug · Management
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on August 22, 2011 has appointed Mr. Sridar Iyengar as an Additional Director on the Board of Directors of the Company with effect from August 22, 2011.
Jul 2011
20 Jul · Consolidated Result Updates - IFRS
20 Jul · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 167571 lacs for quarter ending on 30-JUN-2011 against Rs. 125622 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 45405 lacs for the quarter ending on 30-JUN-2011 against Rs. 24448 lacs for the quarter ending on 30-JUN-2010.1 Jul · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2011.
Jun 2011
22 Jun · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 84,014 equity shares of Rs 5/- each of the Company, fully paid up, on June 22, 2011, to Employees on exercise of their Stock Options as per the following details.(a) 74,026 equity shares of Rs 5/- each pursuant to Dr. Reddy's Employee Stock Option Scheme, 2002.(b)9,988 equity shares of Rs 5/- each underlying 9,988 ADRs pursuant to Dr. Reddy's Employee ADR Stock Option Scheme, 2007.14 Jun · Meeting
Dr. Reddy'S Laboratories Limited has informed the Exchange that the register of members and share transfer books of the Company would remain closed from July 05, 2011 to July 09, 2011 (both days inclusive) for the purpose of Annual General Meeting of the shareholders of the Company and for determining the shareholders who would be entitled for the payment of dividend, if declared at the forthcoming Annual General Meeting, scheduled to be held on July 21, 2011.8 Jun · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company on June 07, 2011 has approved the grant of 1,000 Stock Options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr. Reddy's Employees Stock Option Scheme, 2002."3 Jun · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 139,086 equity shares of Rs.5/- each of the Company, fully paid up, on June 02, 2011, to Non-Executive Directors/Employees on exercise of their Stock Options as per the following details : (1) 115,189 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 23,897 equity shares of Rs.5/- each underlying 23,897 ADRs pursuant to Dr.Reddy's Employees ADR Stock Option Scheme, 2007.
May 2011
16 May · Disclosure
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on May 13, 2011, approved the grant of 9,600 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr.Reddy's Employees Stock Option Scheme, 2002" and also approved the grant of 7,200 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr.Reddy's Employees ADR Stock Option Scheme, 2007". Further the Nomination, Governance & Compensation Committee of the Board of Directors of the Company in their meeting held on May 12, 2011 approved the grant of 251,920 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr.Reddy's Employees Stock Option Scheme 2002" and also approved the grant of 48,860 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr.Reddy's Employees ADR Stock Option Scheme, 2007".13 May · Address Change
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Address of the Registered Office of the Company has been changed as under: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500034, Andhra Pradesh, India.13 May · Dividend
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 13, 2011, have recommended a final dividend of Rs.11.25 (225%) per equity share of Rs.5/- face value, for the financial year 2010-11. The dividend on equity shares, if declared by the shareholders at the ensuing Annual General Meeting, will be credited / despatched on or after July 28, 2011.13 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 521804 lacs for year ending on 31-MAR-2011 against Rs. 440113 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 89331 lacs for the year ending on 31-MAR-2011 against Rs. 84608 lacs for the year ending on 31-MAR-2010.
Apr 2011
21 Apr · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2011 and recommend dividend, if any, for the financial year 2010-11.8 Apr · Results
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Company will announce and publish the audited annual financial results of the Company for the year ended March 31, 2011 instead of unaudited/ audited quarterly financial results for the quarter ended March 31, 2011. In this respect, the audited annual financial results of the Company for the year ended March 31, 2011 would be announced within 60 days from the end of the relevant financial year.7 Apr · Updates
Dr. Reddy'S Laboratories Limited has informed the Exchange that with reference to the issuance of 1,015,516,392 Unsecured, Redeemable, Non-Convertible Bonus Debentures of Rs.5/- each (bonus debentures) issued by the Company pursuant to the Scheme of Arrangement sanctioned by the Hon'ble High Court of Andhra Pradesh at Hyderabad vide Order dated July 19, 2010 (the Scheme), Dr Reddys Laboratories Ltd has informed the Exchange that the Liquidity Facility required to be provided to the Debenture holders in terms of Clause 6.2 of the said Scheme of Arrangement shall be provided by DSP Merrill Lynch Capital Ltd and is scheduled to open on April 07, 2011. Detailed terms and conditions of the above referred Liquidity Facility are available in the Letter of Offer, available on the website of DSP Merrill Lynch Capital Ltd i.e. www.dspml.com
Mar 2011
11 Mar · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 18,985 equity shares of Rs. 5/- each of the Company, fully paid up, on March 11, 2011, to Employees on exercise of their Stock Options.9 Mar · Corporate action
Dr. Reddy'S Laboratories Limited has informed the Exchange that March 18, 2011 has been fixed as "Record Date" for determining the shareholders of the Company who will be entitled to receive 6(six) fully paid unsecured redeemable non-convertible bonus debentures of Rs.5/- each for every existing fully paid equity share of Rs.5/- each of the Company (bonus debentures) pursuant to the Scheme of Arrangement sanctioned by the Hon'ble High Court of Judicature, Andhra Pradesh at Hyderabad on July 19, 2010 which has come into effect on February 01, 2011.The Board of Directors has also fixed 9.25% as the coupon rate on these debentures, payable annually. These debentures would be redeemable, at par, at the end of 36 months from the date of allotment.
Feb 2011
Jan 2011
25 Jan · Consolidated Result Updates - IFRS
25 Jan · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 136479 lacs for quarter ending on 31-DEC-2010 against Rs. 103136 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 26277 lacs for the quarter ending on 31-DEC-2010 against Rs. 16842 lacs for the quarter ending on 31-DEC-2009.10 Jan · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 6,440 equity shares of Rs.5/- each of the Company, fully paid up, on January 08, 2011, to Employees on exercise of their Stock Options as per the following details : (1) 5,300 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 1,140 equity shares of Rs.5/- each underlying 1,140 ADRs pursuant to Dr.Reddy's Employees ADR Stock Option Scheme, 2007.6 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2010.
Dec 2010